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AgingThe free radical theory of aging is almost 60 years old. As mitochondria are the principle source of intracellular
reactive oxygen species (ROS), this hypothesis suggested a central role for themitochondrion innormalmamma-
lian aging. In recent years, however, much work has questioned the importance of mitochondrial ROS in driving
aging. Conversely new evidence points to other facets of mitochondrial dysfunction which may nevertheless
suggest the mitochondrion retains a critical role at the center of a complex web of processes leading to cellular
and organismal aging.
Crown Copyright © 2015 Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Understanding the basis of human aging such that we might ulti-
mately slow its course is one of the great biomedical challenges for
the 21st century. Age is the most important risk factor for most of the
common diseases. Although our knowledge of the aging process re-
mains far from complete, most biogerontologists would now agree
that aging starts with molecular damage, leading to cell, tissue and ulti-
mately organ dysfunction [1,2]. This intrinsic aging process is seen as
forming a ‘tapestry’ upon which the diseases of older age may appear.
The opposing viewswould be that aging is simply the net result of accu-
mulating chronic diseases, or that aging and chronic disease are parallel
but unrelated processes. Perhaps the best known and most long-
standing hypothesis to explain aging is the free radical theory, which
proposes a central role for the mitochondrion as the principle source
of intracellular reactive oxygen species (ROS) leading to mitochondrial
DNA (mtDNA) mutations [3]. Somatic (acquired) mtDNA mutations
have been extensively reported in normal human aging, particularly in
post-mitotic tissue such as skeletal muscle and neurons, but also in rep-
licative tissue such as the colonic crypt, and somatic mtDNA mutations
are also well-described in age-associated neurodegenerative diseases
[4–16]. Corresponding declines in mitochondrial function with age are
also well described. However, these observations do not necessarily
imply a causal relationship between mitochondrial dysfunction and
human aging. In recent years the mitochondrion has once against as-
sumed a pre-eminent role in aging research, driven in part by the devel-
opment of an important mouse model [17,18]. Ironically, much of the
recent work has cast doubt on the mitochondrial free radical theory ofery).
r B.V. This is an open access article uaging, but at the same time, important steps forward have been made
in better understanding the nature of mitochondrial aging. Particularly
important amongst these advances have been an increased awareness
of the origin and natural history of mitochondrial mtDNA mutations in
aging, and an increased ability to link the mitochondrion with other
cellular pathways of aging. As a result we are now arriving at amore nu-
anced and complex understanding of mitochondrial aging, which will
hopefully offer a better chance of effective intervention over the next
decades. Nevertheless there remain a number of unresolved controver-
sies and contradictory observations within the ﬁeld. As such in this in-
troductory review we will consider some recent advances in the ﬁeld,
framed here as a number of the more important unresolved questions.
1.1. Mitochondrial DNA mutations and aging: oxidative damage or replica-
tion error?
Mitochondria are ubiquitous intracellular organelles, present in
almost all mammalian cells. Their primary role is of adenosine
triphosphaste (ATP, themain source of intracellular energy) production
through oxidative phosphorylation. Mitochondria contain their own
small 16.5 kb circular chromosome of DNA encoding several key pro-
teins of themitochondrial respiratory chain [19]. However themajority
of the N1000 predicted mitochondrially targeted proteins are encoded
by the nuclear genome. The mitochondrial respiratory chain comprises
5 multi-subunit complexes, the last of which being ATP synthase. Elec-
trons are exchanged down the chain at increasing reduction potentials
from complexes I through IV, allowing the shuttling of protons across
the mitochondrial membrane creating a proton gradient (membrane
potential). Proton ﬂux through the ATP synthase then provides the
energy which drives ATP synthesis. Some premature electron leak
inevitably occurs at the respiratory chain, resulting in the generationnder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the major sources of ROS [20]. Partial uncoupling (inefﬁciency) of the
respiratory chain allows some proton leak, that is, movement of protons
back into the mitochondrial matrix space that does not occur via ATP
synthase. This makes the respiratory chain less efﬁcient, and physiolog-
ically is used for thermogenesis in brown fat. It has been previously
assumed that uncoupling might result in increased oxidative damage.
States of marked uncoupling are highly deleterious and are associated
with increased ROS. However, mild uncoupling in fact signiﬁcantly
reduces ROS production. It has been suggested (albeit controversially)
that mtDNA subhaplogroups associated with mild uncoupling may
have been selected for their increased thermogenesis in cold climates
[21], but may also confer a longevity advantage due to decreased ROS.
The mutation rate of the mitochondrial genome is estimated to be
~15× that of the nuclear genome. This observation arises from several
considerations: 1) the mitochondrial genome is located on the inner
mitochondrial membrane, adjacent to the respiratory chain, which is
the major source of intracellular ROS production; 2) the mitochondrial
genome lacks protective histones; 3) the DNA repair mechanisms are
limited compared with the nuclear genome. It was therefore long
assumed that ROS was the major source of somatic (acquired) mtDNA
mutations in aging [22,23]. The mitochondrial theory of aging goes on
to postulate that the accumulation of mtDNA mutations will lead to
abnormalities of mitochondrial respiratory chain proteins, causing
partial uncoupling of the respiratory chain. This in turn will lead to
further increased ROS and more mtDNA mutations. Such a ‘vicious
cycle’ hypothesiswould predict an exponential rather than linear trajec-
tory of increasing mtDNA mutation burden, as the initial mutations
would provoke a further mutational ‘burst’. In fact, however, recent
studies suggest that mtDNA mutational burden may not signiﬁcantly
increase at all during human aging, suggesting that a model based on
ROS does not properly explain the natural history of mtDNAmutations
over the human life-course [24,25].
In contrast, recent data have suggested an importance for naturally
occurring replication errors in the formation of age-associated mtDNA
mutations. The characteristic mtDNA mutation type in post-mitotic
tissues (such as muscle and neurons) is the large-scale deletion [26].
Such mutations typically delete several kbs of the mitochondrial
genome, and as this is composed almost entirely of coding genes, such
mutations are highly likely to have a functional effect. Large-scale dele-
tions have a very characteristic distribution within the ‘major arc’ of the
mitochondrial genome, between the origins of replication. The 5′ and 3′
ends of the deletion are clustered around hotspots associated with ho-
mologous repeats [27–29]. The classic example is the 4977 bp ‘common
deletion’ which is associated with 13 bp homologous repeats at each
end. Themajority of deletions are similarly associatedwith homologous
(or near homologous) repeats. Recent physicochemical modeling
suggests that once formed these deleted mtDNA species have inherent
stability [27]. The importance of homologous repeats in deletion forma-
tion suggests a role for single-stranded DNA (ssDNA) intermediates as
these will allow the homologous repeats to anneal. Previously this phe-
nomenon had been thought to arise through the ‘strand asynchronous’
mechanism of mtDNA replication. More recent data suggest however
that double-stranded breaks (DSBs) may be the driving force [30].
These could arise through a variety of processes known to occur natural-
ly including: replication stalling, oxidative damage and UV radiation.
Once aDSBhas formed, repair of themtDNAmoleculewill be attempted
by exonuclease activity which initially creates ssDNA. This can then
anneal at homologous repeats, leading to the mtDNA deletion. This
recent hypothesis however remains controversial and many authors
remain in favor of the previous model of slipped mispairing [31].
1.2. Mitochondrial aging and the ‘mutator’ mouse: proof of causality?
About a decade ago, two very similarmousemodelswere developed
almost simultaneously which have revealed many new insights intomitochondrial aging [17,18]. These mice have a homozygous knock-in
mutation (PolgD257A/D275A) for an error-prone polymerase gamma
(the sole mtDNA polymerase). These mice are referred to as PolgA, or
colloquially as the ‘mutatormice’. They show greatly increased accumu-
lation of somatic mtDNA mutations throughout life, associated with
signiﬁcantly reduced longevity, and a marked progeroid phenotype
that recapitulates the vast majority of phenotypic features of normal
human aging including: kyphosis, reduced fertility, testicular atrophy,
cardiomyopathy, hemopoietic stem cell decline, and frailty.
Prior to the development of the ‘mutator’ mouse the evidence for a
role of mtDNA mutations in aging was largely correlative. That is, al-
though a number of studies had reported somatic mtDNA mutations
in aged persons (as described above), it was possible that these
were simply a marker of chronological rather than biological age. The
mouse models appeared to suggest that mtDNAmutations had a causal
role in aging. Closer scrutiny, however, revealed that the true picture
was likely to be more complex. Although the homozygous mouse has
a clear progeroid phenotype, this is associated with a vastly increased
mtDNA mutation rate. The heterozygous mouse has a modestly in-
creased mutation rate, which appears to exceed that seen in an elderly
human, but has an apparently normal phenotype [32]. These further
observations led some authors to suggest that the ‘mutator’ mouse
could not properly capitulate mtDNA mutations in normal human
aging. Whilst this objection has some currency, the model should not
however be rejected out of hand [33]. A key further consideration is
the great difference in lifespan between humans (N80 years) and mice
(~3 years). MtDNA is constantly turned over throughout life, even in
non-dividing cells, and to the best of our knowledge the rate of turnover
(‘half-life’) of mtDNA is likely to be very similar in mice and humans.
Therefore, the elderly human has experienced vastly more cycles of
mtDNA replication than the agedmouse. Recent data suggest that cycles
of mtDNA replication are likely to play a critical role in the natural
history and functional relevance of mtDNA mutations in aging, as is
discussed in the following section.
Finally there is some controversy over the types ofmutations seen in
the ‘mutator’mouse, the extent towhich these reﬂect those seen in nor-
mal human aging, and which type(s) may drive the phenotype. Linear
forms of mtDNA (which are presumably not being properly degraded)
seem to be particularly common in the mouse model but are not
thought to be an important feature of normal human aging. In contrast
‘canonical’ deletions occur rather rarely if at all in the ‘mutator’ mouse
[34,35].1.3. Clonal expansion: the importance of early mutations?
Normal mammalian cells contain multiple copies of the mitochon-
drial genome, typically hundreds to tens of thousands per cell. Thus
any mtDNA mutation will co-exist with the wild-type within a cell, a
state known as heteroplasmy. Typically the mutant mtDNA must ex-
ceed a heteroplasmy level of ~70% in order to cause a functional defect
(although this may vary somewhat between mutation types) [36,37]. A
somatic mutation will presumably initially exist as a unique species
within a cell. How can it therefore reach a sufﬁcient heteroplasmy
level to cause a functional defect? This process is known as clonal
expansion, and broadly speaking could either occur selectively (i.e. the
mutant mtDNA species expands preferentially at the expense of the
wild-type), or neutrally. A selective expansion, based on differential
size, is plausible for large-scale deletion mutations, and there is some
in vitro evidence to support its occurrence [38]. A neutral theory of clon-
al expansion is based simply on the notion that mtDNA is continuously
turned over in non-dividing cells (termed ‘relaxed replication’) [39–41].
By chance, in aminority of cells amutantmtDNA specieswill increase to
a signiﬁcant level through random drift. This process was predicted
to be slow (progressing over decades), and thus implied a functional
importance for mutations arising early in life [42].
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importance of early mutations and the consequent effects of clonal
expansion. Firstly as discussed above, a key difference between an el-
derly human and the mouse model is the number of cycles of mtDNA
replication. As mtDNA replication is the ‘engine’ of clonal expansion,
very modest initial mutation burdens may nevertheless be sufﬁcient
to ultimately lead to functional defects in elderly humans given the
very long period available for clonal expansion. Secondly, and as alluded
to earlier, a few recent experiments (including our own) using a variety
of modern techniques to measure the total mutational spectrum in tis-
sue homogenates suggest that there may not be a signiﬁcant increase
with aging in humans [24,25]. A larger experiment would however be
required to properly answer this question. Although these observations
seem at ﬁrst paradoxical, the key point is that the number of cells
containing clonally expandedmtDNAmutations does however increase
very signiﬁcantly with age. These data imply that the natural history of
mtDNA mutations in human aging is characterized by the progressive
clonal expansion of a limited pool of early mutations, rather than by
continuous mutagenesis. This notion again argues against the impor-
tance of ROS in driving the accumulation of mtDNA mutations in
aging. In an analogous experiment, we have recently shown that long-
termHIV-infectedpatients (who show certain features of an accelerated
aging phenotype) have an anti-retroviral drug-induced increase in
clonally expandedmtDNAmutations, but not overallmutational burden
[43]. Finally, if early mutations are important, thenwhat if the low-level
‘seeding’ mutations are actually not somatic at all, but maternally
inherited? We have studied pairs of related and unrelated individuals
using massively parallel deep resequencing, and showed that many
ostensibly somatic mtDNA mutations are in fact transmitted down
the maternal line [25]. This observation has recently been nicely
complemented by furtherwork on the ‘mutator’mouse. Itwas observed
that the ‘wild-type’ offspring of a heterozygous ‘mutator’ mother will
have germline mtDNA mutations. These mice show a mildly progeroid
phenotype despite normal polymerase gamma function [44].1.4. ROS: how much is too much?
We have discussed in detail why ROS may no longer be considered
as themajor playing in driving age-associatedmtDNAmutation. Never-
theless it remains likely thatmitochondrial ROSproduction causes other
cellular damage that is plausibly causally associated with the aging
process. Taken together, most data suggest that there is an increase in
oxidative damage in elderly humans [45–47]. Some papers suggest
that antioxidant defenses decrease with age, whereas many suggest
that they remain essentially unchanged [48,49]. It certainly seems likely
that antioxidant defenses probably do not make a compensatory
increase to deal with increased oxidative stress. Calorie restriction
(CR) is the intervention for which the greatest evidence exists for
slowing aging in a variety of model organisms. It was initially thought
that CR would lead to lowered basal metabolic rate (BMR) and hence
decreased ROS production. In fact CR actually can lead to increased
BMR by triggering mitochondrial biogenesis, but the ability to scavenge
ROS increases (in a SIRT3 dependent manner) [50]. Likewise the very
long-lived rodent, the naked mole rat, actually shows increased ROS
comparedwith other rodents, but has increased free radical scavenging,
which does not declinewith age. In a very similar vein, endurance exer-
cise (the other key modality which appears to slow mitochondrial
aging), causes an initial rise in ROS, but this is more than compensated
by the stimulation of biogenesis and an increase in free radical scaveng-
ing [51,52]. It now appears that intracellular ROS may also play some
important roles in intracellular signaling that may actually impact
beneﬁcially on the aging process [53,54]. We are thus coming to a
modern nuanced view that all ROS is not necessarily bad, and that it is
the balance of ROS and scavenging that is probably key, along with the
subcellular location in which the ROS is acting (Fig. 1).If ROS are important in aging, we would expect supplemental
antioxidants to be beneﬁcial. In fact in human studies they have no
beneﬁcial effects and may even be harmful [55]. The problem may be
one of targeting to the mitochondrion. What can transgenic rodents
therefore tell us about the role of ROS in aging? Several models have
tried to determinewhether over-expression of an antioxidant is helpful.
Results have been mixed, with one model where the antioxidant
expression was not mitochondrially-targeted showing no effect,
whereas a targeted antioxidant, such as catalase, appeared to result
in an attenuated rate of aging [56,57]. Conversely a mitochondrial
antioxidant-deﬁcientmouse has a very adverse phenotypewith prema-
ture death due to mitochondrial dysfunction and neurodegeneration
[58]. In the ‘mutator’ mouse ROS production and oxidative damage are
generally not signiﬁcantly increased, suggesting that ROS may not be a
necessary requirement for expression of the progeroid phenotype (al-
though see later discussion regarding stem cell aging) [18,59].1.5. Mitochondrial function in aging: does phenotype follow genotype?
As discussed above, somatic mtDNA mutations will initially exist at
very low heteroplasmy levels. Even considering all mutations present
in a tissue homogenate from an elderly human, they will only represent
a relatively small proportion of the total mtDNA pool. At ﬁrst sight, it is
therefore hard to imagine how such mutations would be sufﬁcient to
cause a functional effect that could drive an aging phenotype. This has
been one of the arguments against a causal role for mtDNA mutations
in normal human aging. Again however, clonal expansion is likely to
be of critical importance. For example, if 10% of mtDNA molecules in a
sample of skeletal muscle tissue aremutated but these are spread even-
ly throughout all the cells, then we would expect a negligible functional
impact as all cells will contain 90% wild-type mtDNA. However, in real-
ity an elderly individual will have 90% of cells which contain almost
entirely wild-type mtDNA, and 10% of cells containing very high levels
of clonally expanded mtDNA mutations. In the latter case, 10% of cells
will experience a functional defect, which could very reasonably lead
to tissue dysfunction. In practice such cells containing clonally expand-
ed mtDNA mutations may be identiﬁed by sequential cytochrome c
oxidase/succinate dehydrogenase (COX/SDH) histochemistry. COX
contains subunits encoded by the mitochondrial genome. In the event
of an mtDNA defect (present at a high enough level within the cell)
COX activity will be lost. Counter-staining with SDH will be retained
as this is encoded entirely by the nuclear genome. COX/SDHhistochem-
istry therefore gives one simplemeasure of mitochondrial function, and
proportional COX defects are seen to progressively increase with age in
a number of post-mitotic tissues in elderly humans, as well as some
replicative tissues such as the colonic crypt [60–64].
When respiratory chain complex activities are measured in the tis-
sue homogenate, the associations with aging are rather mixed. Overall
it seems that complex IV activity will often decrease (in keeping with
the observed histochemical COX defects), but other complex activities
may be retained. Certainly levels of mitochondrial proteins do not
appear to decline during human aging, and it is likely that decreases in
respiratory chain activity are related to decreased efﬁciency. Again,
this could imply an importance for mtDNA mutations. The end result
of the activity of the respiratory chain complexes should be ATP ﬂux.
This can be determine ex vivo [65], or measured in vivo by phosphorus
magnetic resonance spectroscopy (31P MRS) of skeletal muscle [66].
Again data on changes with aging are mixed but it has been suggested
that there is an average decline of 8% per decade in ATP producing
capacity [67–69]. Such decreases in mitochondrial function, as well as
mitochondrial gene expression are also observed in mice, but not in
the very long-lived naked mole rat [70,71]. If cells from an elderly indi-
vidual have less ATP production then presumably they must either be
able to adapt to function with less ATP or theymay producemore ener-
gy through non-oxidative metabolism [72]. This change may result in
Fig. 1. The sedentary elderly mitochondrion. Schematic shows key mitochondrial changes in a sedentary elderly individual. Solid arrows indicate likely casual relationships, whereas
dashed arrows aremore speculative relationships. Green boxes indicate those processeswhich are likely to be subject to improvement by endurance exercise or increasedphysical activity.
Panel insert shows the expected decline in mitochondrial capacity with age in active and sedentary individuals.
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other signaling pathways associated with aging/longevity.
1.6. Mitochondrial biogenesis, aging and decreased physical activity: chick-
en or egg?
To a certain extent,mtDNA copy number,mitochondrial content and
mitochondrial function are correlated. In aging, skeletal muscle mass
decreases frommid-life onwards. The annual rate of loss is said to be al-
most 1%, although the trajectory probably gradually increases with ad-
vancing age [73,74]. Along with this loss of mass, is a reduction in
mitochondrial functional capacity, but the decrease inmitochondrial ca-
pacity is out of proportion, such that themitochondrial density also de-
creases [75,76]. In a similar waymuscle strength per givenmuscle mass
is also seen to fall with age [77]. However it is unclear to what extent
such changes are due to aging per se, as opposed to inactivity. It is
now accepted that many studies showing apparent deterioration in mi-
tochondrial function or contentwith agemay be heavily confounded by
decline in activity with age. In studies where subjects have been strati-
ﬁed by activity levels it is interesting to note that the age-related de-
clines are seen in the sedentary group [78–81]. The active group
shows a verymild decline only.When scrutinized even further however
there is also the suggestion that sedentary young and elderly are not
equivalent in their activity levels. Although neither group is doing regu-
lar exercise, the sedentary young may perform more activity during
day-to-day living. Theremay therefore be someuseful role in the elderly
for increasing their ‘normal’ activities rather than focusing on exercise.
Despite the clear links between inactivity and aging, these observations
could nevertheless be consistent either with a view that inactivity is the
primary driver of mitochondrial decline with age, or that mitochondrial
decline is the initial event, and inactivity then serves as a signal
ampliﬁer.
Clearly there are therefore very strong links between lack of activity/
endurance exercise and age-related mitochondrial decline. A seminal
paper recently showed that the progeroid phenotype in the ‘mutator’
mouse could be essentially entirely ameliorated by endurance exer-
cise [82,83]. The ways in which exercise ameliorates mitochondrial
function are likely to be complex and involve several cellular pathways,
however an AMP kinase/PGC1α pathway mediated increase in mito-
chondrial biogenesis is thought to play a key role. Certainly whenelderly subjects are subjected to exercise training a signiﬁcant improve-
ment in mitochondrial function can be achieved along with an increase
in PGC1α expression [84,85]. In further support of this notion, over-
expression of PGC1α improvesmitochondrial function [86]. Interesting-
ly however, the ability for AMPK-mediated stimulation of biogenesis
does appear to decrease in old age, suggesting that some elderly persons
may have mitochondria that are relatively ‘exercise resistant’ [87].
1.7. Fission and fusion: mitochondrial damage limitation?
In recent years it has become increasingly recognized that mito-
chondria do not exist as isolated organelles, but rather they form into
complexdynamic networkswithin cells. The processes ofmitochondrial
ﬁssion and fusion govern the architecture of these networks. The bal-
ance of ﬁssion and fusion may play an important role in controlling
the expression of deleterious mtDNA mutations within cells. On
the one hand mitochondrial fusion may allow ‘dilution’ of a mutant
mtDNA species into a pool of wild-type molecules, thus reducing the
functional effect. On the other hand ﬁssion may allow the segregation
of abnormal mitochondria within the cell which can then be the subject
of selective mitophagy [88–91]. Currently it is not very clear to what
extent there may be age-associated changes in mitochondrial ﬁssion
and fusion or to what extent any such changes might be deleterious or
adaptive. A study has reported that Mfn2 expression (a key mediator
of mitochondrial fusion) is reduced in aged persons [92]. There is a
suggestion of some decrease in mitophagy with aging, which may
contribute to the accumulation of mutant mtDNA [93–95].
1.8. Sarcopenia: is it mitochondrially mediated?
Sarcopenia is the classical skeletal muscle phenotype of aging and
has been associated with the adverse physical state of frailty [96,97].
Sarcopenia is often measured by various imaging modalities demon-
strating an age-associated reduction in muscle mass. Age-associated
loss of muscle mass and the correlation with mitochondrial function
has already been described above. Plausibly this process might at least
in part be explained by loss of muscle ﬁbers through apoptosis [98,99].
Mitochondria are clearly intimately linked with apoptosis, and an in-
crease in caspase-independent apoptosis with age is well described,
both in skeletal muscle and more generally [97,100–102]. In contrast,
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[102]. Several of these studies have been able to draw broad links be-
tween markers of apoptosis, sarcopenia and mitochondrial function.
In contrast however, the presence of sarcopenia has if anything been
more closely linked with other systemic features of aging, such as in-
ﬂammation, than it has with mitochondrial dysfunction. For example,
a gene expression study of sarcopenia showed signals from inﬂammato-
ry and apoptotic pathways without a clear mitochondrial signal [103].
1.9. A role for mitochondria in replicative senescence?
Stem cell senescence is considered an important facet of biological
aging. Recent work has investigated whether mitochondrial aging
might also contribute to stem cell aging. Interestingly, the initial de-
scriptions of the ‘mutator’mouse suggested that ROSwas not increased,
however further work tells us that the mouse exhibits stem cell aging
(both hemopoietic and neural) [104]. This occurs very early (during
fetal development) and therefore precedes both the onset of the
progeroid phenotype and the measureable mitochondrial functional
defects. The phenomenon may therefore be driven by an early increase
in ROS within the stem cells, particularly as antioxidant treatment was
seen to ameliorate the stem cell defect.
Recently links have been made between mitochondrial aging and
other cellular pathways that are thought to play a key role in aging in-
cluding IGF-1 signaling andmTOR pathways [105,106]. These pathways
have upstream effects on mitochondrial metabolism, and also mediate
some of the longevity beneﬁts of CR. Finally, links are now emerging be-
tween mitochondrial function, telomere shortening and the p53 path-
ways, thus joining many of the remaining dots of cellular aging [107].
2. Conclusions
It is clear that mitochondria retain a central role in the complex bal-
ance of cellular processes that may ultimately contribute to aging. The
articles in this themed issue will explore various aspects of this role in
much greater detail. A key challenge for the next 10 years will be to
clinically translate the novel observations from model systems.
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